Vaccination against HPV: boosting coverage and tackling misinformation
- PMID: 33058497
- PMCID: PMC7931130
- DOI: 10.1002/1878-0261.12808
Vaccination against HPV: boosting coverage and tackling misinformation
Abstract
The availability of human papillomavirus (HPV) vaccines and screening tests has raised the possibility of globally eliminating cervical cancer, which is caused by HPV. Cervical cancer is a very common malignancy worldwide, especially among deprived women. High vaccination coverage is key to the containment and eventual elimination of the infection. Public HPV vaccination programmes in Italy and Denmark were swiftly established and are among the most successful worldwide. Still, in both countries, it has been challenging to achieve and maintain the recommended coverage of > 80% in girls. In a well-studied Italian region, vaccination coverage in girls at age 15 years (World Health Organization's gold standard) reached 76% in 2015 but decreased to 69% in 2018, likely due to work overload in public immunization centres. In Denmark, doubts about safety and efficacy of the HPV vaccine generated a decline in coverage among girls age 12-17, from 80% in 2013 down to 37% in 2015, when remedial actions made it rise again. Insights from these two countries are shared to illustrate the importance of monitoring coverage in a digital vaccine registry and promptly reacting to misinformation about vaccination.
Keywords: HPV; cervical cancer; coverage; misinformation; social media; vaccination.
© The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
Conflict of interest statement
The authors declare no conflict of interest.
Figures



Similar articles
-
Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths.Vaccine. 2014 Feb 3;32(6):733-9. doi: 10.1016/j.vaccine.2013.11.049. Epub 2013 Nov 26. Vaccine. 2014. PMID: 24291200
-
Potential benefit of extended dose schedules of human papillomavirus vaccination in the context of scarce resources and COVID-19 disruptions in low-income and middle-income countries: a mathematical modelling analysis.Lancet Glob Health. 2023 Jan;11(1):e48-e58. doi: 10.1016/S2214-109X(22)00475-2. Lancet Glob Health. 2023. PMID: 36521952 Free PMC article.
-
Modelling the population-level impact of vaccination on the transmission of human papillomavirus type 16 in Australia.Sex Health. 2007 Sep;4(3):147-63. doi: 10.1071/sh07042. Sex Health. 2007. PMID: 17931528
-
Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening.Vaccine. 2007 Apr 20;25(16):3007-13. doi: 10.1016/j.vaccine.2007.01.016. Epub 2007 Jan 18. Vaccine. 2007. PMID: 17292517 Review.
-
Prophylactic human papillomavirus vaccination and primary prevention of cervical cancer: issues and challenges.Clin Microbiol Infect. 2012 Oct;18 Suppl 5:64-9. doi: 10.1111/j.1469-0691.2012.03946.x. Epub 2012 Aug 6. Clin Microbiol Infect. 2012. PMID: 22862799 Review.
Cited by
-
A systematic literature review of human papillomavirus vaccination strategies in delivery systems within national and regional immunization programs.Hum Vaccin Immunother. 2024 Dec 31;20(1):2319426. doi: 10.1080/21645515.2024.2319426. Epub 2024 Feb 27. Hum Vaccin Immunother. 2024. PMID: 38410931 Free PMC article.
-
Does Vaccination Protect against Human Papillomavirus-Related Cancers? Preliminary Findings from the United States National Health and Nutrition Examination Survey (2011-2018).Vaccines (Basel). 2022 Dec 10;10(12):2113. doi: 10.3390/vaccines10122113. Vaccines (Basel). 2022. PMID: 36560523 Free PMC article.
-
Parental perceptions of the HPV vaccine for prevention of anogenital and oropharyngeal cancers.Vaccine X. 2023 Apr 2;14:100298. doi: 10.1016/j.jvacx.2023.100298. eCollection 2023 Aug. Vaccine X. 2023. PMID: 37113741 Free PMC article.
-
Improving HPV Vaccine Coverage in Tennessee: Addressing Barriers and Expanding Access for Mid-Adults.Pathogens. 2025 Mar 25;14(4):311. doi: 10.3390/pathogens14040311. Pathogens. 2025. PMID: 40333055 Free PMC article. Review.
-
Trends of cervical cancer at global, regional, and national level: data from the Global Burden of Disease study 2019.BMC Public Health. 2021 May 12;21(1):894. doi: 10.1186/s12889-021-10907-5. BMC Public Health. 2021. PMID: 33975583 Free PMC article.
References
-
- World Health organization (2014) Human papillomavirus vaccines: WHO position paper, October 2014. Wkly Epidemiol Rec 89, 465–491. - PubMed
-
- Bruni L, Diaz M, Barrionuevo‐Rosas L, Herrero R, Bray F, Bosch FX, de Sanjose S & Castellsague X (2016) Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Glob Health 4, e453–e463. - PubMed
-
- Nguyen‐Huu NH, Thilly N, Derrough T, Sdona E, Claudot F, Pulcini C & Agrinier N (2020) Human papillomavirus vaccination coverage, policies, and practical implementation across Europe. Vaccine 38, 1315–1331. - PubMed